• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

3537 例冠心病患者结局分析:心血管事件的整合医学。

Analysis on outcome of 3537 patients with coronary artery disease: integrative medicine for cardiovascular events.

机构信息

Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.

出版信息

Evid Based Complement Alternat Med. 2013;2013:162501. doi: 10.1155/2013/162501. Epub 2013 Aug 1.

DOI:10.1155/2013/162501
PMID:23983773
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3747377/
Abstract

Aims. To investigate the treatment of hospitalized patients with coronary artery disease (CAD) and the prognostic factors in Beijing, China. Materials and Methods. A multicenter prospective study was conducted through an integrative platform of clinical and research at 12 hospitals in Beijing, China. The clinical information of 3537 hospitalized patients with CAD was collected from September 2009 to May 2011, and the efficacy of secondary prevention during one-year followup was evaluated. In addition, a logistic regression analysis was performed to identify some factors which will have independent impact on the prognosis. Results. The average age of all patients was 64.88 ± 11.97. Of them, 65.42% are males. The medicines for patients were as follows: antiplatelet drugs accounting for 91.97%, statins accounting for 83.66%, β -receptor blockers accounting for 72.55%, ACEI/ARB accounting for 58.92%, and revascularization (including PCI and CABG) accounting for 40.29%. The overall incidence of cardiovascular events was 13.26% (469/3537). The logistic stepwise regression analysis showed that heart failure (OR, 3.707, 95% CI = 2.756-4.986), age ≥ 65 years old (OR, 2.007, 95% CI = 1.587-2.53), and myocardial infarction (OR, 1.649, 95% CI = 1.322-2.057) were the independent risk factors of others factors for cardiovascular events that occurred during followup of one-year period. Integrative medicine (IM) therapy showed the beneficial tendency for decreasing incidence of cardiovascular events, although no statistical significance was found (OR, 0.797, 95% CI = 0.613~1.036). Conclusions. Heart failure, age ≥ 65 years old, and myocardial infarction were associated with an increase in incidence of cardiovascular events, and treatment with IM showed a tendency for decreasing incidence of cardiovascular events.

摘要

目的。研究中国北京住院冠心病(CAD)患者的治疗方法和预后因素。材料和方法。通过中国北京 12 家医院的临床和研究综合平台,进行了一项多中心前瞻性研究。2009 年 9 月至 2011 年 5 月期间,收集了 3537 例住院 CAD 患者的临床信息,并评估了一年随访期间的二级预防效果。此外,还进行了逻辑回归分析,以确定对预后有独立影响的一些因素。结果。所有患者的平均年龄为 64.88 ± 11.97 岁。其中,65.42%为男性。患者使用的药物如下:抗血小板药物占 91.97%,他汀类药物占 83.66%,β受体阻滞剂占 72.55%,ACEI/ARB 占 58.92%,血管重建术(包括 PCI 和 CABG)占 40.29%。心血管事件的总发生率为 13.26%(469/3537)。逻辑逐步回归分析表明,心力衰竭(OR,3.707,95%CI=2.756-4.986)、年龄≥65 岁(OR,2.007,95%CI=1.587-2.53)和心肌梗死(OR,1.649,95%CI=1.322-2.057)是随访 1 年内发生其他心血管事件的独立危险因素。尽管没有统计学意义(OR,0.797,95%CI=0.613-1.036),但综合医学(IM)治疗显示出降低心血管事件发生率的趋势。结论。心力衰竭、年龄≥65 岁和心肌梗死与心血管事件发生率的增加相关,IM 治疗显示出降低心血管事件发生率的趋势。

相似文献

1
Analysis on outcome of 3537 patients with coronary artery disease: integrative medicine for cardiovascular events.3537 例冠心病患者结局分析:心血管事件的整合医学。
Evid Based Complement Alternat Med. 2013;2013:162501. doi: 10.1155/2013/162501. Epub 2013 Aug 1.
2
Analysis on outcome of 5284 patients with coronary artery disease: the role of integrative medicine.分析 5284 例冠心病患者的结果:整合医学的作用。
J Ethnopharmacol. 2012 Jun 1;141(2):578-83. doi: 10.1016/j.jep.2011.08.071. Epub 2011 Sep 8.
3
Effectiveness of Integrative Medicine Therapy on Coronary Artery Disease Prognosis: A Real-World Study.整合医学疗法对冠状动脉疾病预后的有效性:一项真实世界研究。
Chin J Integr Med. 2019 Jan;25(1):9-15. doi: 10.1007/s11655-016-2454-9. Epub 2016 Apr 28.
4
Balancing benefit against risk in the choice of therapy for coronary artery disease. Lesson from prospective, randomized, clinical trials of percutaneous coronary intervention and coronary artery bypass graft surgery.冠状动脉疾病治疗选择中风险与获益的权衡。经皮冠状动脉介入治疗和冠状动脉旁路移植术前瞻性随机临床试验的经验教训。
Minerva Cardioangiol. 2003 Oct;51(5):585-97.
5
[Current status and influence factors of ACEI/ARB application in elderly coronary heart disease outpatients complicated with diabetes mellitus in China].[中国老年冠心病合并糖尿病门诊患者应用ACEI/ARB的现状及影响因素]
Zhonghua Yi Xue Za Zhi. 2016 Sep 27;96(36):2917-2922. doi: 10.3760/cma.j.issn.0376-2491.2016.36.016.
6
Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.现代他汀类药物时代,血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在无心力衰竭的冠状动脉疾病中的疗效:一项随机对照试验的荟萃分析。
Cardiovasc Drugs Ther. 2016 Apr;30(2):189-98. doi: 10.1007/s10557-016-6652-7.
7
Five-year outcomes of surgical or percutaneous myocardial revascularization in diabetic patients.糖尿病患者心脏旁路手术或经皮冠状动脉介入治疗的 5 年结果。
Int J Cardiol. 2013 Sep 30;168(2):1028-33. doi: 10.1016/j.ijcard.2012.10.030. Epub 2012 Nov 17.
8
9
Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.心肌梗死伴非阻塞性冠状动脉疾病患者的二级预防和长期预后的医学治疗。
Circulation. 2017 Apr 18;135(16):1481-1489. doi: 10.1161/CIRCULATIONAHA.116.026336. Epub 2017 Feb 8.
10
Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study.日本冠状动脉疾病(JCAD)研究中药物对心血管事件的影响。
Circ J. 2007 Dec;71(12):1835-40. doi: 10.1253/circj.71.1835.

引用本文的文献

1
ABCB1 confers resistance to carboplatin by accumulating stem-like cells in the G2/M phase of the cell cycle in p53 ovarian cancer.ABCB1通过在p53基因缺失的卵巢癌细胞周期的G2/M期积累干细胞样细胞,赋予对卡铂的抗性。
Cell Death Discov. 2025 Apr 2;11(1):132. doi: 10.1038/s41420-025-02435-7.
2
How to Use Statins in Secondary Prevention of Atherosclerotic Diseases: from the Beneficial Early Initiation to the Potentially Unfavorable Discontinuation.如何在动脉粥样硬化疾病的二级预防中使用他汀类药物:从早期有益的起始用药到潜在不利的停药
Cardiovasc Drugs Ther. 2023 Apr;37(2):353-362. doi: 10.1007/s10557-021-07233-8. Epub 2021 Aug 4.
3
The utilization of nonprescription medications in Saudi patients with cardiovascular diseases.沙特心血管疾病患者非处方药的使用情况
Saudi Pharm J. 2018 Jan;26(1):120-124. doi: 10.1016/j.jsps.2017.10.003. Epub 2017 Oct 3.
4
Effectiveness of Integrative Medicine Therapy on Coronary Artery Disease Prognosis: A Real-World Study.整合医学疗法对冠状动脉疾病预后的有效性:一项真实世界研究。
Chin J Integr Med. 2019 Jan;25(1):9-15. doi: 10.1007/s11655-016-2454-9. Epub 2016 Apr 28.

本文引用的文献

1
Is diabetes mellitus a heart disease equivalent in women? Results from an international study of postmenopausal women in the Raloxifene Use for the Heart (RUTH) Trial.糖尿病在女性中相当于心脏病吗?雷洛昔芬用于心脏(RUTH)试验中绝经后女性的一项国际研究结果。
Circ Cardiovasc Qual Outcomes. 2013 Mar 1;6(2):164-70. doi: 10.1161/CIRCOUTCOMES.112.966986. Epub 2013 Mar 12.
2
Rehospitalization for heart failure: problems and perspectives.心力衰竭再住院治疗:问题与展望。
J Am Coll Cardiol. 2013 Jan 29;61(4):391-403. doi: 10.1016/j.jacc.2012.09.038. Epub 2012 Dec 5.
3
Use of complementary therapies in cardiovascular disease.心血管疾病中的补充疗法应用。
Am J Cardiol. 2013 Feb 1;111(3):339-45. doi: 10.1016/j.amjcard.2012.10.010. Epub 2012 Nov 24.
4
Diabetes and coronary heart disease: a risk factor for the global epidemic.糖尿病与冠心病:全球流行病的一个风险因素。
Int J Hypertens. 2012;2012:697240. doi: 10.1155/2012/697240. Epub 2012 Oct 18.
5
Clinical pathways based on integrative medicine in chinese hospitals improve treatment outcomes for patients with acute myocardial infarction: a multicentre, nonrandomized historically controlled trial.中国医院基于中西医结合的临床路径改善急性心肌梗死患者的治疗效果:一项多中心、非随机历史对照试验。
Evid Based Complement Alternat Med. 2012;2012:821641. doi: 10.1155/2012/821641. Epub 2012 Sep 13.
6
[Characteristics of out-of-hospital acute coronary heart disease deaths of Beijing permanent residents at the age of 25 or more from 2007 to 2009].[2007年至2009年北京市25岁及以上常住人口院外急性冠心病死亡特征]
Zhonghua Xin Xue Guan Bing Za Zhi. 2012 Mar;40(3):199-203.
7
Coronary heart disease mortality in China: age, gender, and urban-rural gaps during epidemiological transition.中国冠心病死亡率:流行病学转变过程中的年龄、性别和城乡差距。
Rev Panam Salud Publica. 2012 Apr;31(4):317-24. doi: 10.1590/s1020-49892012000400008.
8
Current situation and perspectives of clinical study in integrative medicine in china.中国整合医学临床研究的现状与展望。
Evid Based Complement Alternat Med. 2012;2012:268542. doi: 10.1155/2012/268542. Epub 2012 Feb 21.
9
Analysis on outcome of 5284 patients with coronary artery disease: the role of integrative medicine.分析 5284 例冠心病患者的结果:整合医学的作用。
J Ethnopharmacol. 2012 Jun 1;141(2):578-83. doi: 10.1016/j.jep.2011.08.071. Epub 2011 Sep 8.
10
Clinical effect of Astragalus granule of different dosages on quality of life in patients with chronic heart failure.不同剂量黄芪颗粒对慢性心力衰竭患者生活质量的临床疗效。
Chin J Integr Med. 2011 Feb;17(2):146-9. doi: 10.1007/s11655-011-0647-9. Epub 2011 Mar 9.